After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door. Fulcrum Therapeutics’ restructure ...
With few treatments available for sickle cell disease, encouraging early clinical data for a Fulcrum Therapeutics drug made it one to watch. But another medicine from the same drug class was recently ...
Fulcrum Therapeutics (FULC) lost nearly 50% of its value in extended trading after the company disclosed plans to discontinue the development of its lead asset, pociredir, for sickle cell disease in ...
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy. Sign up here. Pociredir ...
Fulcrum has been left with no option but to abandon its ambitions for pociredir in SCD and “explore strategic alternatives.” (Photo by Sarah Silbiger/Getty Images) Fulcrum Therapeutics has scrapped ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
June 1 (Reuters) - Fulcrum Therapeutics (FULC.O), opens new tab said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised ...
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is working on the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The team is in various stages of ...
A dispute between brothers at the helm of a prominent San Antonio real estate development company has erupted into a multimillion-dollar lawsuit, with allegations of deception, betrayal and actions ...
Anthropic releases Claude Opus 4.7, narrowly retaking lead for most powerful generally available LLM
Anthropic is publicly releasing its most powerful large language model yet, Claude Opus 4.7, today — as it continues to keep an even more powerful successor, Mythos, restricted to a small number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results